Epilepsy.com Editor-In-Chief Dr. Joseph Sirven interviews Aprecia CEO Don Wetherhold about Spritam, the first 3D printed drug.
In early August, Aprecia announced that the Food and Drug Administration (FDA) has approved SPRITAM® (levetiracetam) tablets as adjunctive therapy in the treatment of partial onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in people with epilepsy. Spritam uses ZipDose® Technology platform, which produces a porous formulation through 3D printing; this allows the formulation to quickly disintegrate with a sip of liquid. Spritam will be available as 250mg, 500mg, 750mg, and 1000mg strengths in 60-count cartons (6x10) in a spearmint flavor. It is expected to be available for prescription in the first quarter of 2016.